Genetic testing for pheochromocytoma-associated syndromes

Area of Science:

• Endocrinology and Oncology
• Neuroscience and Genetics

Background:

• Pheochromocytoma and paraganglioma (PGL) are rare tumors originating from the autonomic nervous system.
• These tumors are associated with various inherited syndromes, including multiple endocrine neoplasia type 2 (MEN 2), von Hippel-Lindau disease (VHL), neurofibromatosis 1 (NF 1), and paraganglioma syndromes (PGL1, PGL3, PGL4).

Purpose of the Study:

• To review recent advancements in the clinical characterization and genetic testing for syndromes associated with PGL.
• To provide recommendations for efficient genetic testing strategies in patients with PGL based on tumor characteristics and prevalence data.

Main Methods:

• Review of current literature on clinical features and genetic associations of PGL syndromes.
• Analysis of tumor characteristics and prevalence data across different genetic syndromes.
• Formulation of evidence-based recommendations for genetic testing protocols.

Main Results:

• The prevalence and clinical manifestations of PGL differ significantly among associated genetic syndromes.
• Mutational analysis of susceptibility genes (RET, VHL, NF1, SDHD, SDHC, SDHB) is crucial for risk stratification.
• Genetic testing can inform the assessment of risks for tumor multifocality, malignant PGL, and secondary malignancies.

Conclusions:

• Understanding the genetic underpinnings of PGL syndromes is essential for comprehensive patient management.
• Tailored genetic testing strategies can optimize diagnostic yield and inform clinical decision-making.
• Early identification of genetic predisposition facilitates proactive surveillance and management of associated risks.